| Lauren Dick, PHARMD | |
|
1016 Lakecrest Rd, Lawrence, KS 66049-3320 | |
| (785) 218-9287 | |
| Not Available |
| Full Name | Lauren Dick |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 1016 Lakecrest Rd, Lawrence, Kansas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053765255 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 1-16765 (Kansas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Lauren Dick, PHARMD 1016 Lakecrest Rd, Lawrence, KS 66049-3320 Ph: () - | Lauren Dick, PHARMD 1016 Lakecrest Rd, Lawrence, KS 66049-3320 Ph: (785) 218-9287 |
News Archive
Speaking at the American Society for Microbiology's (ASM) Biodefense and Emerging Diseases Research meeting in Washington, D.C., on Wednesday, Ron Fouchier, the leader of the team at Erasmus Medical Center in the Netherlands that genetically altered the H5N1 bird flu virus, making it transmissible among ferrets and "touching off public fears of a pandemic, said that the virus he created was neither as contagious nor as dangerous as people had been led to believe, prompting the United States government to ask that the experiments be re-evaluated by a government advisory panel that recommended in December that certain details of the work be kept secret and not published," the New York Times reports.
A team of researchers led by Samir Mehta, MD, chief of the Orthopaedic Trauma & Fracture Service at the Perelman School of Medicine at the University of Pennsylvania, has received a $2.5 million grant from the Congressionally Directed Medical Research Program (CDMRP), provided through the U.S. Department of Defense (DoD), to begin Phase 2 human trials of a study that examines the effective treatment of post-surgical orthopedic infections using Microbion Corporation's topical BisEDT drug.
Threshold Pharmaceuticals, Inc. today announced that it has initiated a multi-center, randomized, controlled, crossover Phase 2 clinical trial of TH-302 in combination with gemcitabine in patients with first line pancreatic cancer. TH-302 is a proprietary tumor selective Hypoxia-Activated Prodrug that specifically targets tumor hypoxia.
A new study analyzing tweets about COVID-19 found that users with larger social networks tend to use fewer uncivil remarks when they have more positive responses from others.
› Verified 1 days ago
Jakob Ready, PHARM.D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3421 W 6th St, Lawrence, KS 66049 Phone: 785-841-9000 | |
Carrie Lynn Williams, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2336 Ridge Ct, Ste C, Lawrence, KS 66046 Phone: 785-841-1950 Fax: 785-841-1051 | |
William J Anderson, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1410 Kasold Dr, Ste A16, Lawrence, KS 66049 Phone: 785-843-8555 Fax: 785-843-0645 | |
Nikita Gandhi, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2300 Iowa St, Lawrence, KS 66046 Phone: 785-832-1112 | |
Dr. Michelle Wessling, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 325 Maine St, Lawrence, KS 66044 Phone: 785-505-5127 | |
Bridget Ellen Gillespie, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 400 W 23rd Street, Lawrence, KS 66046 Phone: 785-832-8388 |